Focused On-demand Library for DNA excision repair protein ERCC-6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

ATP-dependent helicase ERCC6; Cockayne syndrome protein CSB

Alternative UPACC:

Q03468; D3DX94; E7EV46; Q5W0L9


DNA excision repair protein ERCC-6, also known as ATP-dependent helicase ERCC6 or Cockayne syndrome protein CSB, plays a pivotal role in transcription-coupled nucleotide excision repair. It facilitates the removal of RNA polymerase II-blocking lesions from active genes, thereby ensuring the integrity of genetic information. Its DNA-binding ability alters DNA conformation, promoting repair complex formation and recruiting essential nucleotide excision repair proteins.

Therapeutic significance:

ERCC-6 is crucial in diseases like Cockayne syndrome B, Cerebro-oculo-facio-skeletal syndrome 1, De Sanctis-Cacchione syndrome, age-related macular degeneration, and UV-sensitive syndrome 1. These conditions underscore the protein's significance in DNA repair mechanisms. Understanding the role of DNA excision repair protein ERCC-6 could open doors to potential therapeutic strategies for these genetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.